Mizuho Markets Americas LLC Has $6.45 Million Stake in Haemonetics Corporation $HAE

Mizuho Markets Americas LLC cut its position in Haemonetics Corporation (NYSE:HAE) by 43.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 132,314 shares of the medical instruments supplier’s stock after selling 103,700 shares during the period. Mizuho Markets Americas LLC owned about 0.27% of Haemonetics worth $6,449,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC bought a new stake in shares of Haemonetics during the third quarter worth $334,000. Versant Capital Management Inc lifted its holdings in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Haemonetics by 4.0% during the third quarter. Nordea Investment Management AB now owns 107,827 shares of the medical instruments supplier’s stock worth $5,143,000 after buying an additional 4,106 shares during the period. State of Alaska Department of Revenue grew its holdings in shares of Haemonetics by 44.2% during the third quarter. State of Alaska Department of Revenue now owns 8,141 shares of the medical instruments supplier’s stock worth $395,000 after buying an additional 2,496 shares in the last quarter. Finally, Cardinal Capital Management lifted its stake in Haemonetics by 8.1% in the 3rd quarter. Cardinal Capital Management now owns 22,121 shares of the medical instruments supplier’s stock valued at $1,078,000 after acquiring an additional 1,652 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

NYSE HAE opened at $72.17 on Monday. The company has a market cap of $3.38 billion, a P/E ratio of 21.10, a PEG ratio of 1.36 and a beta of 0.29. The company has a fifty day simple moving average of $79.57 and a 200 day simple moving average of $65.91. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. During the same period in the previous year, the business posted $1.12 EPS. The business’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HAE. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, January 9th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Mizuho increased their target price on shares of Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.40.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.